Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.05.2024 | Case report

Pembrolizumab

Myocarditis

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Kuhnly NM, et al. A case study of myopericarditis due to immune checkpoint inhibitor therapy: Proposed surveillance and management. Journal of the American Association of Nurse Practitioners 35 : 317-321, No. 5, May 2023. Available from: URL: 10.1097/JXX.0000000000000860 Kuhnly NM, et al. A case study of myopericarditis due to immune checkpoint inhibitor therapy: Proposed surveillance and management. Journal of the American Association of Nurse Practitioners 35 : 317-321, No. 5, May 2023. Available from: URL: 10.1097/JXX.0000000000000860
Metadaten
Titel
Pembrolizumab
Myocarditis
Publikationsdatum
01.05.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-58464-1

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Ketamine

Case report

Isoniazid

Case report

Lenvatinib

Case report

Multiple drugs